Alnylam Pharmace. buy Biotechhunter
Summary
This prediction ended on 26.06.20 with a price of €139.00. With a performance of 6.53%, the BUY prediction by Biotechhunter for Alnylam Pharmace. closed with a slight gain. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | 0.372% | 0.372% | -25.497% | 17.261% |
iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.